中低收入国家哮喘管理:变革的呼声
哮喘是儿童最常见的非传染性疾病,也是成人最常见的疾病之一,绝大多数患者居住在中低收入国家(LMIC),这些国家的哮喘相关发病率和死亡率过高。必要吸入药物(尤其含吸入性糖皮质激素(ICS)者)常不可及或不可负担,这解释了全球大部分可预防的哮喘发病和死亡负担。针对LMIC的指南通常基于过时假设,即每周症状<1-3次的患者不需要(或不能从)ICS中获益;即使处方ICS,许多患者因可及性和可负担性问题仅使用口服或吸入短效β2受体激动剂(SABA)。从诊断开始对所有严重程度(从轻度到重度)采用单一ICS-福莫特罗吸入器管理策略,可能克服SABA过度使用/依赖并减少症状和严重急性发作负担,但ICS-福莫特罗吸入器目前在LMIC可及性很差或不可负担。迫切需要务实临床试验证据来评估该策略及其他策略在这些国家改善哮喘护理的可行性和成本效益。全球哮喘护理中的健康不平等剥夺了许多儿童、青少年和成人的健康生活并增加其死亡风险,尽管存在高效治疗方法,这是不可接受的。需要世界卫生大会关于普遍获得可负担有效哮喘护理的决议,以聚焦关注和投资解决这一需求。
要点
- LMIC哮喘负担重,必要ICS常不可及或不可负担
- LMIC指南基于过时假设,轻症患者可能未获ICS
- 单一ICS-福莫特罗策略可能减少SABA过度使用
核心结论
- LMIC哮喘相关发病和死亡负担过高,主要因必要吸入药物不可及或不可负担。
- 从诊断开始对所有严重程度采用单一ICS-福莫特罗吸入器策略可能减少SABA过度使用和严重急性发作。
- 需要世界卫生大会决议促进普遍获得可负担有效哮喘护理。
研究设计与样本
- 原文为Eur Respir J发表的论述性文章,未报告系统检索或原始研究设计。
主要发现
- 绝大多数哮喘患者居住在中低收入国家(LMIC),这些国家哮喘相关发病率和死亡率过高。
- 必要吸入药物(尤其含ICS者)常不可及或不可负担,导致全球大部分可预防哮喘发病和死亡。
- 针对LMIC的指南通常基于过时假设:每周哮喘症状<1-3次的患者不需要(或不能从)ICS中获益。
- 即使处方ICS,许多患者因可及性和可负担性问题仅使用口服或吸入SABA。
- ICS-福莫特罗吸入器目前在LMIC可及性很差或不可负担。
关键数值与推荐
- 针对LMIC的指南通常基于过时假设:每周哮喘症状<1-3次的患者不需要(或不能从)ICS中获益。
- 从诊断开始对所有严重程度(从轻度到重度)采用单一ICS-福莫特罗吸入器管理策略。
临床怎么用
- 在LMIC应关注ICS可及性和可负担性,避免仅依赖SABA管理哮喘。
- 可考虑从诊断开始对所有严重程度使用单一ICS-福莫特罗吸入器策略,但需本地可行性评估。
- 需开展务实临床试验评估该策略及其他策略在LMIC的可行性和成本效益。
局限性
- 原文未报告系统检索或原始研究数据。
- ICS-福莫特罗吸入器在LMIC目前可及性很差或不可负担。
- 需要务实临床试验证据评估策略的可行性和成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asthma is the most common noncommunicable disease in children, and among the most common in adults. The great majority of people with asthma live in low and middle income countries (LMICs), which have disproportionately high asthma-related morbidity and mortality. Essential inhaled medications, particularly those containing inhaled corticosteroids (ICS), are often unavailable or unaffordable, and this explains much of the global burden of preventable asthma morbidity and mortality. Guidelines developed for LMICs are generally based on the outdated assumption that patients with asthma symptoms <1-3 times per week do not need (or benefit from) ICS. Even when ICS are prescribed, many patients manage their asthma with oral or inhaled short-acting β2-agonists (SABA) alone, owing to issues of availability and affordability. A single ICS-formoterol inhaler-based approach to asthma management for all severities of asthma, from mild to severe, starting at diagnosis, might overcome SABA overuse/over-reliance and reduce the burden of symptoms and severe exacerbations. However, ICS-formoterol inhalers are currently very poorly available or unaffordable in LMICs. There is a pressing need for pragmatic clinical trial evidence of the feasibility and cost-effectiveness of this and other strategies to improve asthma care in these countries. The global health inequality in asthma care that deprives so many children, adolescents and adults of healthy lives and puts them at increased risk of death, despite the availability of highly effective therapeutic approaches, is unacceptable. A World Health Assembly Resolution on universal access to affordable and effective asthma care is needed to focus attention and investment on addressing this need.
引用
- Mortimer K, Reddel HK, Pitrez PM, et al. Asthma management in low and middle income countries: case for change. Eur Respir J. 2022. PMID: 35210321. doi:10.1183/13993003.03179-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。